403 related articles for article (PubMed ID: 24856285)
1. [Cost of multiple sclerosis in France].
Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
[TBL] [Abstract][Full Text] [Related]
2. Geographic variations of multiple sclerosis in France.
Fromont A; Binquet C; Sauleau EA; Fournel I; Bellisario A; Adnet J; Weill A; Vukusic S; Confavreux C; Debouverie M; Clerc L; Bonithon-Kopp C; Moreau T
Brain; 2010 Jul; 133(Pt 7):1889-99. PubMed ID: 20551111
[TBL] [Abstract][Full Text] [Related]
3. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
4. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
5. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
Rotstein Z; Hazan R; Barak Y; Achiron A
Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database.
Vandhuick O; Payet M; Préaud E; Lortet-Tieulent J; Raguideau F; Chevreuil O; van Hille B; Kwiatkowski A
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1135-1144. PubMed ID: 34165377
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
9. Peripheral arterial obliterative disease. Cost of illness in France.
Montron A; Guignard E; Pelc A; Comte S
Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):51-9. PubMed ID: 10175985
[TBL] [Abstract][Full Text] [Related]
10. [Cost evaluation of a model for integrated care of seriously mentally ill patients].
Fischer F; Hoffmann K; Mönter N; Walle M; Beneke R; Negenborn S; Weinmann S; Willich SN; Berghöfer A
Gesundheitswesen; 2014 Feb; 76(2):86-95. PubMed ID: 23737155
[TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database.
Tuppin P; Rivière S; Rigault A; Tala S; Drouin J; Pestel L; Denis P; Gastaldi-Ménager C; Gissot C; Juillière Y; Fagot-Campagna A
Arch Cardiovasc Dis; 2016; 109(6-7):399-411. PubMed ID: 27079468
[TBL] [Abstract][Full Text] [Related]
13. Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
15. [Direct and indirect costs of fractures due to osteoporosis in Austria].
Dimai HP; Redlich K; Schneider H; Siebert U; Viernstein H; Mahlich J
Gesundheitswesen; 2012 Oct; 74(10):e90-8. PubMed ID: 22422076
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
Bruno D; Marc D; Ouarda P; Dominique S; Marc S; Laurène C; Khalil J; Jonathan E; Francis G
Mult Scler Relat Disord; 2019 Nov; 36():101396. PubMed ID: 31525627
[TBL] [Abstract][Full Text] [Related]
18. [Reimbursed health expenditures during the last year of life, in France, in the year 2008].
Ricci P; Mezzarobba M; Blotière PO; Polton D
Rev Epidemiol Sante Publique; 2013 Feb; 61(1):29-36. PubMed ID: 23318018
[TBL] [Abstract][Full Text] [Related]
19. [The cost of treatment of multiple sclerosis in Colombia].
Romero M; Arango C; Alvis N; Suarez JC; Duque A
Value Health; 2011; 14(5 Suppl 1):S48-50. PubMed ID: 21839899
[TBL] [Abstract][Full Text] [Related]
20. Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation--an Italian perspective.
Allegra C
Curr Med Res Opin; 2003; 19(8):761-9. PubMed ID: 14687448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
